Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals.
Atopic dermatitis
genitals
tralokinumab
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
ppublish
Résumé
Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area. to evaluate the efficacy of tralokinumab in AD patients with genital involvement. Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16. out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores. despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.
Sections du résumé
BACKGROUND
UNASSIGNED
Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area.
OBJECTIVE
UNASSIGNED
to evaluate the efficacy of tralokinumab in AD patients with genital involvement.
METHODS
UNASSIGNED
Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16.
RESULTS
UNASSIGNED
out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores.
CONCLUSION
UNASSIGNED
despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.
Identifiants
pubmed: 38724042
doi: 10.1080/09546634.2024.2351489
doi:
Substances chimiques
Antibodies, Monoclonal
0
tralokinumab
GK1LYB375A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM